This page uses content from Wikipedia and is licensed under CC BY-SA.
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) that can change the behavior of immune cells so they protect dopamine-producing cells rather than attacking them. The drug is being studied for its potential use for Parkinson's disease.
LBT-3627 specifically targets the VIP2 receptor, unlike VIP. The drug also affects microglia. In addition, LBT-3627 is more durable in the body compared to VIP.
History and development
Scientists at the University of Nebraska Medical Center and Longevity Biotech, Inc. first demonstrated the use of the drug in mouse models.
A phase I trial for humans was planned for 2017, but as of 2018 it was still in the preclinical development stage.
- ^ a b Paddock, Catharine (December 17, 2015). "New drug that protects dopamine cells raises treatment hope for Parkinson's". Medical News Today. Retrieved December 18, 2015.
- ^ a b "Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies". PR Newswire. December 16, 2015. Retrieved December 21, 2015.
- ^ Azevedo, Margarida (December 21, 2015). "New Drug Candidate Shows Promise in Animal Model of Parkinson's". Parkinson's News Today. Retrieved December 21, 2015.
- ^ a b c Block, Jonathan (December 17, 2015). "Drug That Protects Dopamine Cells Eyed as Parkinson's Treatment". Phychiatry Advisor. Retrieved December 21, 2015.
- ^ "Research programme: peptide-based therapeutics - Longevity Biotech". AdisInsight. January 8, 2018.
Highest Development Phases: Preclinical : Neurological disorders; Type 2 diabetes mellitus